Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13
Jennifer D Hamilton1, Manuel A R Ferreira1, Wei Keat Lim1
1Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Allergy
|May 15, 2026
Summary
Multiple type-2-inflammation-associated diseases (T2IDs) share common drivers and respond well to IL4/IL13 blockade. This study confirms shared genetic and transcriptomic signatures across T2IDs, explaining their unified response to dupilumab.
Area of Science:
- Immunology
- Genetics
- Dermatology
Background:
- Multiple type-2-inflammation-associated diseases (T2IDs) often co-occur, suggesting a shared underlying immune dysregulation.
- Emerging research indicates that the interleukin (IL)-4/IL-13 pathway may be a common driver for many T2IDs.
Purpose of the Study:
- To systematically compare multiple T2IDs using large datasets.
- To confirm the role of IL-4/IL-13 pathway over-activation as a common driver for T2IDs.
- To correlate shared molecular signatures with clinical response to IL-4/IL-13 blockade.
Main Methods:
- Comprehensive quantitative analyses of large, independent datasets (real-world and clinical trial data).
- Evaluation of co-prevalence, genetic predispositions, and transcriptomic signatures across T2IDs.
- Summary of clinical trial data for dupilumab (anti-IL-4/IL-13 antibody).
Main Results:
- Asthma, atopic dermatitis, eosinophilic esophagitis, nasal polyps, and prurigo nodularis are highly interrelated T2IDs.
- These T2IDs share genetic predispositions and transcriptomic signatures indicative of IL-4/IL-13 pathway over-activation.
- T2IDs demonstrated uniformly positive clinical responses to dupilumab treatment.
Conclusions:
- Over-activation of the IL-4/IL-13 pathway is a key causative driver for multiple T2IDs.
- Shared genetic and transcriptomic signatures explain the consistent clinical response to IL-4/IL-13 blockade.
- These signatures may help identify other IL-4/IL-13-mediated diseases or T2-inflammatory subpopulations.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...